Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms

Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms 
MONTREAL, Dec. 5, 2012 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX and TSX: VRX) announced today that the company has reached 
agreement on terms of a revised North American aesthetics arrangement with 
Galderma S.A.  Under the terms of the revised agreement, Galderma will 
continue to supply Restylane® and Perlane® to Valeant, under the terms and 
conditions Galderma currently supplies those products to Medicis 
Pharmaceutical Corporation (NYSE: MRX).  In addition, Valeant will make an 
upfront payment and a royalty to Galderma on sales of Sculptra®.  Among other 
things, the agreement provides for resolution of all claims asserted in 
Galderma's pending litigation relating to Valeant's acquisition of Medicis. 
In addition, Valeant will obtain North American rights to Emervel®, an 
innovative, next generation family of hyaluronic acid dermal fillers that are 
specifically designed to provide both patient tolerability and long-lasting 
correction of facial lines, contouring and volume loss or lip enhancement.  
The terms of the agreement are subject to the closing of Valeant's pending 
acquisition of Medicis, which is expected to occur on December 11, 2012. 
"We are pleased to have found a collaborative solution with Galderma to create 
a long-term working relationship between our two companies," said J. Michael 
Pearson, chairman and chief executive officer.  "The combination of Restylane, 
Perlane and Sculptra, along with the future addition of Emervel, delivers a 
broad and strong array of aesthetic product offerings for doctors and 
patients. With this agreement, Valeant and Galderma will continue to build a 
leading aesthetics presence in North America." 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of neurology, 
dermatology and branded generics.  More information about Valeant 
Pharmaceuticals International, Inc. can be found at 
Forward-Looking Statements 
This press release may contain forward-looking statements. These 
forward-looking statements relate to, among other things, the closing of the 
Medicis transaction, the final resolution of existing litigation, and the 
addition of Emervel to the product portfolio. Forward-looking statements can 
generally be identified by the use of words such as "believe," "anticipate," 
"expect," "estimate," "intend," "continue," "plan," "project," "will," "may," 
"should," "could," "would," "target," "potential," and other similar 
expressions.  In addition, any statements that refer to expectations, 
projections or other characterizations of future events or circumstances are 
forward-looking statements.  Actual results may differ materially from those 
expressed or implied in such statements.  Important factors that could cause 
actual results to differ materially from these expectations include, among 
other things, the satisfaction of customary closing conditions with respect to 
the closing of the Medicis transaction, the approval by FDA of Emervel and the 
addition of Emervel to the product portfolio, and the risk factors as detailed 
from time to time in Valeant's reports filed with the Securities and Exchange 
Commission and the Canadian Securities Administrators. 
Contact Information:  Laurie W. Little 949-461-6002 
PRN Photo Desk, 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
-0- Dec/05/2012 21:31 GMT
Press spacebar to pause and continue. Press esc to stop.